Moberg Pharma (MOB) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
MOB-015 internationalization advanced with Terclara® launched in Israel, the first market outside the Nordics; preparations with Karo Healthcare progressed toward additional launches.
Q3 and 9M revenue increased YoY, while operating and net losses narrowed; cash and cash equivalents were SEK 204.5 million at September 30, 2026.
Financial highlights
Q3 net revenue was SEK 5.8 million (4.0); gross profit SEK 3.8 million (2.4); EBIT SEK -3.2 million (-6.0); net loss SEK 1.7 million (4.3).
9M net revenue was SEK 16.5 million (11.5); gross profit SEK 10.8 million (6.7); EBIT SEK -9.8 million (-19.9); net loss SEK 6.3 million (14.5).
Diluted EPS was SEK -0.04 in Q3 (-0.09) and SEK -0.13 for 9M (-0.31).
Q3 other operating income of SEK 1.8 million (0.1) primarily reflected FX adjustments on USD holdings; exposure was reduced as most holdings shifted to SEK.
Outlook and guidance
Karo 2027 launch preparations advanced; first production batches were manufactured, with final batch release pending and initial deliveries expected around year-end.
Regulatory, manufacturing and supply planning are progressing in parallel; additional launches are planned over coming years, subject to local approvals.
MOB-015 has approvals in 14 countries; partners cover Europe, APAC, Canada, China and Israel, with Karo agreements spanning 19 European markets, four APAC countries and China.
A further U.S. clinical study is considered necessary before an FDA application; near-term focus remains approved and partnered markets, while study options and potential partners are evaluated.
Latest events from Moberg Pharma
- Patented topical treatment achieves 76% cure rate and rapid market leadership in Europe.MOB
Investor presentation - Market leadership, 76% cure rate, and global expansion drive strong growth outlook.MOB
Q2 2026 - Revenue rose and losses narrowed in Q1 2026, with major APAC expansion and Nordic market gains.MOB
Q1 2026 - TerclaraⓇ rapidly became a market leader in Europe with a 76% cure rate and broad approvals.MOB
Stora Aktiedagarna 2026 - TerclaraⓇ leads the European nail fungus market with high cure rates and rapid commercial success.MOB
Investor presentation - TerclaraⓇ achieved Nordic market leadership and set the stage for broad European expansion.MOB
Q4 2025 - North American phase III study missed its endpoint; focus shifts to EU market growth.MOB
Study Update - Terclara led Sweden's Q3 market, fueling growth as U.S. Phase 3 expectations were revised down.MOB
Q3 2024 - Swedish market leadership, European expansion, and SEK 300M impairment after U.S. trial delay.MOB
Q4 2024